The Need for RSV Prophylaxis in LMICs

Pediatrics. 2024 Oct 1;154(4):e2024067062. doi: 10.1542/peds.2024-067062.
No abstract available

MeSH terms

  • Antiviral Agents / therapeutic use
  • Developing Countries*
  • Humans
  • Infant
  • Infant, Newborn
  • Palivizumab / therapeutic use
  • Respiratory Syncytial Virus Infections* / prevention & control

Substances

  • Antiviral Agents
  • Palivizumab